We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Microarray Technology Enables Sequencing of Neanderthal DNA

By LabMedica International staff writers
Posted on 20 May 2010
By utilizing an advanced DNA capture technique, genomic researchers have succeeding in mapping a portion of the Neanderthal genome and comparing it to that of modern humans.

Investigators at the Max Planck Institute (Munich, Germany) , Cold Spring Harbor Laboratory (Cold Spring Harbor, NY, USA), and Agilent Technologies, Inc. More...
(Santa Clara, CA, USA) used Agilent's microarray system to sequence nearly 14,000 protein-coding positions inferred to have changed on the human lineage since the last common ancestor shared with chimpanzees.

Generally, it has been extremely difficult to work with ancient DNA due in part to chemical aging of the DNA molecules but even more so due to severe bacterial contamination of the samples. Now, in a study published in the May 7, 2010, issue of the journal Science, investigators from the three institutions described the use of array-hybridization capture technology, a process that enriched Neanderthal DNA sequences while depleting contaminant DNA. Thus, they were able to enrich Neanderthal protein-coding regions where differences occurred on the human evolutionary lineage up to 190,000-fold. By generating the sequence of one Neanderthal and 50 present-day humans, the investigators identified 88 amino acid substitutions that have become fixed in humans since our divergence from the Neanderthals.

"Attaining good coverage of the Neanderthal genome had been a problem due to DNA contamination from microbes over the years,” said senior investigator Dr. Svante Paabo, professor of evolutionary genetics at the Max Planck Institute. "Simply sequencing, without first enriching for the genome, often did not work, especially where the contamination levels were high. Array-hybridization capture technology was originally reported by the Cold Spring Harbor Laboratory group and is the subject of a longstanding collaboration with Agilent. The team recognized this as a promising method for recovering large regions of targeted sequence from Neanderthal samples. The method can also be used more widely with many other kinds of human remains.”

In a second article in the same issue of Science, the investigators presented their first detailed analysis of the draft sequence of the Neanderthal genome, which now includes more than three billion nucleotides collected from the bones of three female Neanderthals who lived in Croatia more than 38,000 years ago. By comparing this composite Neanderthal genome with the complete genomes of five living humans from different parts of the world, the investigators found that both Europeans and Asians share 1-4% of their nuclear DNA with Neanderthals, but that Africans do not. This suggests that early modern humans interbred with Neanderthals after moderns left Africa, but before they spread into Asia and Europe.

Related Links:

Max Planck Institute
Cold Spring Harbor Laboratory
Agilent Technologies



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.